These findings imply that claudin1 is a promising therapeutic target for EGFR-TKI resistant NSCLC cells, underscoring the significance of claudin1 as a predictor of EGFR-TKI resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.